【摘 要】
：
目的:评价重组人白细胞介素-11(rhIL-11)预防髓母细胞瘤术后放疗所致血小板减少的疗效和不良反应.方法:采用随机对照研究方法,将患者随机分为A组(rhIL-11预防治疗组)和B组(对照组).A组患者放射治疗过程中血小板计数＜100×109/L时或血小板计数较放射治疗前基线水平下降＞50％即开始按50μg·kg-1·d-1剂量给予rhIL-11皮下注射,每日1次,连续应用,直至血小板数≥200
论文部分内容阅读
目的:评价重组人白细胞介素-11(rhIL-11)预防髓母细胞瘤术后放疗所致血小板减少的疗效和不良反应.
方法:采用随机对照研究方法,将患者随机分为A组(rhIL-11预防治疗组)和B组(对照组).A组患者放射治疗过程中血小板计数＜100×109/L时或血小板计数较放射治疗前基线水平下降＞50％即开始按50μg·kg-1·d-1剂量给予rhIL-11皮下注射,每日1次,连续应用,直至血小板数≥200×109/L时停药.B组患者不予预防性应用rhIL-11治疗,但当血小板计数＜50×109/L时则按50μg·kg1·d1剂量给予rhIL-11皮下注射治疗,每日1次,连续应用,直至血小板数≥100×109/L时停药.
结果:有54例可评价疗效,rhIL-11可显著升高髓母细胞瘤术后放射治疗中血小板的最低值(P＜0.01),显著缩短血小板减少症的持续时间(P＜0.01),显著减少血小板的输注次数(P＜0.01);显著缩短放射治疗所需的时间(P＜0.01).主要不良反应注射部位疼痛(27.1％)、硬结(19.8％)、红肿(15.1％)、水肿(7.9％)、乏力(7.2％)、心悸(4.8％)等,大都程度较轻,无其他严重不良反应.
结论:rhIL-11具有明显的促血小板生成作用,可显著减少髓母细胞瘤患者术后放射治疗过程中血小板减少的发生,保证放射治疗的顺利进行.不良反应较轻且较易处理.
其他文献
The dosimetric and clinical outcomes of intensity modulated radiation therapy for primary mediastinal large B-cell lymphoma after chemotherapy have not been reported previously, to our knowledge.This
The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large-cell lymphoma (ALCL) treated with doxorubicin-based chemotherapy and radiotherapy.Forty-six a
The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicincontaining chemoth
Purpose: To evaluate compliance with postmastectomy radiation therapy (PMRT) guidelines in breast cancer patients in China over a 10-year period.Methods and Materials: A hospital-based, nationwide, mu
The dosimetric and clinical outcomes of intensity modulated radiation therapy (IMRT) for patients with early stage Waldeyers ring NK/T-cell lymphoma (WRNKTCL) have not previously been reported.Thirty
Objective To provide evidence that could improve management of breast cancer, we conducted a multi-center retrospective epidemiological study to investigate the status of and changes in postmastectomy
目的:对12例三维适形或调强治疗的肺癌病例进行回顾性肺NTCP分析,加深对肺癌三维适形及调强治疗认识.为同等条件下不同治疗方案的正常组织并发症概率(NTCP)物理学的优选,提供一定依据.方法:引用第三方NTCP计算实例,验证NTCP软件计算办法和可行性.而后对12例肺癌病例(4例为三维适形治疗,8例为调强治疗)进行NTCP计算和统计学分析.结果:调强治疗病例患肺NTCP,双肺NTCP与三维适形治疗
文章简单叙述了OUR-XGD旋转式伽玛刀的电气控制原理，对其故障现象进行分析，指出此次伽玛刀的故障，主要是由ACS控制器长年的运行(9年时间)，内部的芯片老化接连出现了2个问题而引起设备故障，在进行了硬件的组装后，设备能够进行正常的通讯，通过对电气的线路的更改和软件程序的修改，很好地解决了该设备的故障，保证了病人的正常治疗。
To investigate the feasibility, efficiency, and delivery accuracy of volumetric modulated arc therapy with constant dose rate (VMAT-CDR) for whole-pelvic radiotheraw (WPRT) of endometrial cancer.The n
Background: The purpose of the present study was to investigate the feasibility of using volumetric modulated arc therapy with SmartArc (VMAT-S) to achieve radiation delivery efficiency higher than th